Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.View HST guidance
How we identify topics
We only consider drugs for very rare conditions. The majority of our topics are identified by the National Institute for Health Research Innovation Observatory. They aim to notify the Department of Health and Social Care of key, new and emerging healthcare technologies that might need to be referred to NICE against the following timeframes:
- new drugs, in development, at 20 months to marketing authorisation
- new indications, at 15 months to marketing authorisation.
A single HST evaluation can only cover a single technology for a single indication.
Provisional evaluation topics chosen
The Department of Health and Social Care (DHSC) produces a list of provisional evaluation topics.
Consultees and commentators identified
NICE works with the DHSC to develop a scope. The scope defines the disease, the patients and the technology covered by the evaluation and the questions it aims to answer. Consultees and commentators are requested to comment on the draft scope.
Evaluation topics referred
The DHSC refers HST evaluation topics to NICE.
The manufacturer or sponsor of the technology is invited to provide an evidence submission. NICE also invites all non-manufacturer consultees to submit a statement on the potential clinical effectiveness and value for money of a treatment.
Evidence Review Group (ERG) report prepared
NICE commissions an independent academic centre to technically review the evidence submission and prepare an ERG report.
Evaluation report prepared
This includes all of the evidence that will be looked at by the Evaluation Committee. This evidence includes:
- the ERG report and any comments received on it
- written submissions
- personal statements from patient experts and clinical specialists.
An independent advisory committee considers the evaluation report and hears evidence from nominated clinical experts, patients and carers. Evaluation Committee discussions are held in public.
Evaluation consultation document (ECD) produced if needed
The Evaluation Committee makes its provisional recommendations in the ECD. An ECD will be produced only if the recommendations from the Evaluation Committee are restrictive. A restrictive recommendation will be one that is more limited than the instructions for use that accompany the technology. Consultees and commentators have four weeks to comment on the ECD. The ECD is also made available on our website so health professionals and members of the public can comment on it.
Final evaluation determination (FED) produced
The Evaluation Committee considers the comments on the ECD if produced, then makes its final recommendations in the FED on how the technology should be used in the NHS in England. Consultees can appeal against the final recommendations in the FED.
If there are no appeals, or an appeal is not upheld, the final recommendations are issued as NICE guidance.
We're reviewing and, where necessary, updating the methods and processes that we use to produce guidance around health technologies.
The consultation on the case for change to the methods is now open until 18 December 2020. Tell us your views.
Charges for our highly specialised technology evaluations came into effect on 1 April 2019
EQ-5D-5L: NICE Position Statement (updated November 2018)
Past consultations on our ways of working
Find out more about the Highly Specialised Technology Evaluation Committee, including how to attend a meeting.